Bagsværd, Denmark, 25 October 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme i
It's not that difficult to spread your investments out across many companies and hope for the best over a long time horizon. Another took a different route by making a bet on ARK Genomic Revolution ETF (NYSEMKT: ARKG) in the hope of owning the first healthcare industry trillion-dollar market cap company. Jason Hawthorne (Novo Nordisk): Novo Nordisk is one of three large drug manufacturers that account for the majority of insulin production in the world.
GSK vs. NVO: Which Stock Is the Better Value Option?